Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
Cani L, Scott S, Roberts D, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. Haematologica 2025 PMID: 40905083, DOI: 10.3324/haematol.2025.288187.Peer-Reviewed Original ResearchIntravenous immunoglobulinAnti-BCMAImmune effector cell-associated neurotoxicity syndromePrevention of cytokine release syndromeBispecific antibodiesSingle-center retrospective studyMonthly intravenous immunoglobulinIntravenous immunoglobulin administrationCytokine release syndromeMedian Follow-UpSingle-center experienceAssociated with infection riskInfection riskPrimary prophylaxisHerpes zosterViral loadRetrospective studyNeurotoxicity syndromeCumulative incidenceFollow-upMultivariate analysisRisk factorsProphylactic measuresPatientsBsAb
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply